JPWO2019236931A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2019236931A5 JPWO2019236931A5 JP2020568472A JP2020568472A JPWO2019236931A5 JP WO2019236931 A5 JPWO2019236931 A5 JP WO2019236931A5 JP 2020568472 A JP2020568472 A JP 2020568472A JP 2020568472 A JP2020568472 A JP 2020568472A JP WO2019236931 A5 JPWO2019236931 A5 JP WO2019236931A5
- Authority
- JP
- Japan
- Prior art keywords
- pharmaceutical composition
- composition according
- antibody
- cancer
- protein
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862682202P | 2018-06-08 | 2018-06-08 | |
| US62/682,202 | 2018-06-08 | ||
| PCT/US2019/035922 WO2019236931A1 (en) | 2018-06-08 | 2019-06-07 | Recombinant herpes simplex virus for cancer immunotherapy |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021527072A JP2021527072A (ja) | 2021-10-11 |
| JPWO2019236931A5 true JPWO2019236931A5 (https=) | 2022-06-15 |
| JP2021527072A5 JP2021527072A5 (https=) | 2022-06-15 |
| JP7373209B2 JP7373209B2 (ja) | 2023-11-02 |
Family
ID=67070913
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020568472A Active JP7373209B2 (ja) | 2018-06-08 | 2019-06-07 | がん免疫治療のための組換え単純ヘルペスウイルス |
Country Status (8)
| Country | Link |
|---|---|
| US (2) | US12329794B2 (https=) |
| EP (1) | EP3801583B1 (https=) |
| JP (1) | JP7373209B2 (https=) |
| KR (1) | KR102906757B1 (https=) |
| CN (1) | CN112243378B (https=) |
| AU (1) | AU2019282755B2 (https=) |
| CA (1) | CA3142073A1 (https=) |
| WO (1) | WO2019236931A1 (https=) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN111635913B (zh) * | 2020-06-16 | 2022-03-04 | 广东东阳光药业有限公司 | 构建体及其应用 |
| CN113862229A (zh) * | 2020-06-30 | 2021-12-31 | 东莞市东阳光生物药研发有限公司 | 一种重组单纯疱疹病毒及其构建方法 |
| CN113943752A (zh) * | 2020-07-15 | 2022-01-18 | 东莞市东阳光生物药研发有限公司 | 构建体、敏感性提高的溶瘤病毒及其应用 |
| CN114075574A (zh) * | 2020-08-19 | 2022-02-22 | 广东东阳光药业有限公司 | 构建体、溶瘤病毒及其应用 |
| TW202521570A (zh) * | 2023-08-25 | 2025-06-01 | 大陸商勃林格殷格翰動物保健（中國）有限公司 | 用於禽類疫苗的新型ｄｅｖ載體 |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE60115600T2 (de) * | 2000-01-21 | 2006-07-20 | Biovex Ltd. | Virusstämme für die onkolytische behandlung von krebs |
| US7264814B2 (en) * | 2001-05-09 | 2007-09-04 | M's Science Corporation | Composition and method for treating cancer using herpes virus |
| GB0714578D0 (en) * | 2007-07-26 | 2007-09-05 | Crusade Lab Ltd | Viruses |
| ES2861450T3 (es) | 2015-07-20 | 2021-10-06 | Virttu Biologics Ltd | Uso del virus del herpes simple oncolítico en combinación con un inhibidor de puntos de control inmunitario, en el tratamiento del cáncer |
| US20170319638A1 (en) | 2016-05-06 | 2017-11-09 | Virttu Biologics Limited | Treatment of cancer |
-
2019
- 2019-06-07 US US17/054,338 patent/US12329794B2/en active Active
- 2019-06-07 AU AU2019282755A patent/AU2019282755B2/en active Active
- 2019-06-07 CA CA3142073A patent/CA3142073A1/en active Pending
- 2019-06-07 CN CN201980038180.3A patent/CN112243378B/zh active Active
- 2019-06-07 KR KR1020207033859A patent/KR102906757B1/ko active Active
- 2019-06-07 EP EP19733912.0A patent/EP3801583B1/en active Active
- 2019-06-07 JP JP2020568472A patent/JP7373209B2/ja active Active
- 2019-06-07 WO PCT/US2019/035922 patent/WO2019236931A1/en not_active Ceased
-
2025
- 2025-05-23 US US19/216,880 patent/US20250339482A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021527072A5 (https=) | ||
| TWI839805B (zh) | 一種重組單純皰疹病毒及其用途 | |
| JP2021119797A5 (https=) | ||
| Bai et al. | A review of HSV pathogenesis, vaccine development, and advanced applications | |
| JP6424145B2 (ja) | ウイルス株 | |
| Kinchington et al. | Herpes simplex virus and varicella zoster virus, the house guests who never leave | |
| Lachmann | Herpes simplex virus‐based vectors | |
| Rolinski et al. | Immunological aspects of acute and recurrent herpes simplex keratitis | |
| AU2001226951A1 (en) | Virus strains for the oncolytic treatment of cancer | |
| Mody et al. | Herpes simplex virus: a versatile tool for insights into evolution, gene delivery, and tumor immunotherapy | |
| WO2007052029A1 (en) | Oncolytic herpes virus vectors | |
| Watanabe | Medical application of herpes simplex virus | |
| US12509662B2 (en) | Generation regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use | |
| Nash | T cells and the regulation of herpes simplex virus latency and reactivation | |
| JPWO2019236931A5 (https=) | ||
| Hukkanen et al. | Cytokines in experimental herpes simplex virus infection | |
| US20220002680A1 (en) | Regulatable fusogenic oncolytic herpes simplex virus type 1 virus and methods of use | |
| Hukkanen et al. | Host responses to herpes simplex virus and herpes simplex virus vectors | |
| Spencer et al. | Herpes simplex virus: A versatile tool for insights into evolution, gene delivery, and tumor immunotherapy | |
| EP3594328A1 (en) | Recombinant herpes simplex virus and use thereof | |
| Sarkar | Modulation of type-i interferon mediated immune response: a novel innate immune evasion strategy of equine herpesvirus 1 | |
| Hayashi | The ultimate terminus of evolutional symbiosis leaves a flaw: blinding herpetic stromal keratitis | |
| Israyelyan | Novel Oncolytic Herpesviruses for Breast Cancer Treatment | |
| Kim | Herpes simplex virus type 1 glycoprotein gm and the membrane associated protein UL11 are required for virus-induced cell fusion and efficient virus entry | |
| Guedon et al. | Herpes simplex virus and varicella zoster virus, the house guests who never leave. |